Compare Cytokinetics Inc (CYTK) vs TotalEnergies SE (TTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs TotalEnergies SE — how do they compare? Cytokinetics Inc trades at $82.52 (market cap $11.12B), while TotalEnergies SE trades at $80.41 (market cap $180.15B). The key difference: TotalEnergies SE is far larger — about 16.2× Cytokinetics Inc's market cap, and TotalEnergies SE pays a 5.21% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | TTE | |
|---|---|---|
Market Cap | $11.12B | $180.15B |
Sector | Technology | Energy |
52-Week High | $87.26 | $93.60 |
52-Week Low | $33.23 | $57.39 |
Enterprise Value | $11.59B | $214.29B |
Dividend Yield | — | 5.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
TotalEnergies (TTE) trades at $81.21, up 3.45% today, with a neutral technical signal and bearish moving averages. The company reported Q1 2026 EPS of $2.45, beating expectations, but revenue has declined from $263.3B in 2022 to $182.3B in 2025. Valuation ratios are attractive with a P/E of 12.05 and EV/EBITDA of 4.93. Recent news highlights strategic moves in LNG and solar divestments to focus on larger renewable projects.
The outlook for TTE is supported by strong cash flow generation and a 'Buy' consensus from 57.6% of analysts, but risks include declining revenue trends, geopolitical exposure, and regulatory pressures. The stock offers value with solid profitability and shareholder returns via dividends, yet investors should weigh execution risks in its energy transition strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
